CLDWW · Calidi Biotherapeutics, Inc. · Investor Relations
Substantial doubt about the company's ability to continue as a going concern.
“The Company estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 13, 2026
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-10-19 | Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026 |
| 2026-09-25 | Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency |
| 2026-09-17 | Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering |
| 2026-09-08 | Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference |
| 2026-08-13 | Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights |
| 2026-07-27 | Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference |
| 2026-07-21 | Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers |
| 2026-07-20 | Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 |
| 2026-07-08 | Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 |
| 2026-06-24 | Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit |
| 2026-06-23 | Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors |
| 2026-06-16 | Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study |
| 2026-06-08 | Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026 |
| 2026-05-26 | Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting |
| 2026-05-22 | Calidi Biotherapeutics Provides Required NYSE American Disclosure |
| 2026-05-14 | Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights |
| 2026-05-13 | Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston |
| 2026-04-29 | Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI |
| 2026-04-21 | Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 |
| 2026-04-20 | Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 |
| 2026-04-15 | Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms |
| 2026-04-14 |
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) - Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present at the Internation Oncolytic Virus Conference (IOVC) in Reykjavik, Iceland on April 28 th , 2026. The Company will present data on its RedTail platform and its lead compound CLD-401. RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. Data presented at IOVC by Duong Nguyen, PhD, Senior Director, Translational Research and Innovation for Calidi, will showcase the ability of the RedTail extracellular enveloped and CD55-overexpressing virus (EEV) to avoid immune clearance, replicate only in target cells, and deliver high concentrations of genetic medicine |
| 2026-04-07 |
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) - Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Boston, Massachusetts on May 14, 2026. The Company will present data on its RedTail platform. RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. Data presented at the ASGCT meeting by Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi, will showcase the ability of the RedTail extracellular enveloped and CD55-overexpressing virus (EEV) to avoid immune clearance, replicate only in target cells, and deliver high concentrations |
| 2026-04-02 |
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) - Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will showcase new data on CLD-401, a systemically delivered oncolytic virus that is designed to express high levels of IL-15 superagonist (“IL-15 SA”) only in the tumor microenvironment (“TME”), currently in IND-enabling studies. CLD-401 is the lead candidate from the Company’s RedTail platform, a systemically delivered virotherapy platform designed to selectively target tumors, remodel the TME, and enable high-level expression of therapeutic genetic payloads directly within the tumor. CLD-401 is engineered to express high levels of IL-15 SA, a known T- and NK-cell activator, in the TME. Data at AACR will detail the pattern of |
| 2026-04-01 |
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) - Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will demonstrate new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment (TME). RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors, remodel the TME, and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL-15 SA, a known T and NK-cell activator, in the TME. The Company expects to file an IND for CLD-401 |